UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
||
(Address of principal executive offices) | (Zip Code) |
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On March 31, 2024, Zymeworks Inc. (the “Company”) removed Dr. Christopher Astle from the positions of Senior Vice President and Chief Financial Officer, including as the Company’s principal financial officer and principal accounting officer, effective immediately.
In connection with Dr. Astle’s removal, effective March 31, 2024, the Company’s board of directors (the “Board”) appointed Mr. Kenneth Galbraith, the Company’s current Chair of the Board, President and Chief Executive Officer, as the Company’s interim Chief Financial Officer. In connection with this appointment, Mr. Galbraith will continue in his roles as Chair of the Board, President and Chief Executive Officer and assume the duties of the Company’s principal financial officer and principal accounting officer, until his successor is appointed or until his earlier resignation or removal. The Company has initiated a search for a new Chief Financial Officer.
Mr. Galbraith is 61 years old and has served as the Company’s Chief Executive Officer and Chair of the Board since January 2022. In addition, Mr. Galbraith has served as the Company’s President since June 2023 and previously served as the Company’s President from January 2022 to August 2022. Mr. Galbraith was a Managing Director at Five Corners Capital, Inc., which he founded in 2013, from February 2021 until January 2022. He served as Executive in Residence at Syncona Limited from April 2021 until January 2022, and has served as an advisor to Syncona since May 2023. He served as Chief Executive Officer of Liminal BioSciences Inc. (formerly Prometic Life Sciences Inc.), a publicly held company, from April 2019 to November 2020, continuing as an advisor to that company from November 2020 to February 2021. He also served as Chief Executive Officer of Fairhaven Pharmaceuticals Inc. from June 2017 to April 2019. Mr. Galbraith has served as a director of several publicly held companies, including MacroGenics, Inc. from July 2008 until January 2022, Profound Medical Corp. from January 2017 to May 2023, and Celator Pharmaceuticals, Inc. from July 2008 to October 2013. He has also served as a director of several privately held companies. Previously, he joined Ventures West Capital in 2007 and founded Five Corners Capital Inc. in 2013 to manage the continued operations of the Ventures West Investment Funds. Mr. Galbraith has over 35 years of experience serving as an executive, director, investor and adviser to companies in the biotechnology, medical device, pharmaceutical and healthcare sectors. Mr. Galbraith received his B.Comm. from the University of British Columbia.
The compensatory and other material terms of Mr. Galbraith’s employment with the Company will remain unchanged in connection with the foregoing. For information regarding Mr. Galbraith’s existing compensation arrangements, please refer to the information contained in the section titled “Item 11. Executive Compensation—Executive Employment Arrangements and Potential Payments upon Termination or Change in Control” in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 6, 2024, which information is incorporated herein by reference.
There are no arrangements or understandings between Mr. Galbraith and any other persons pursuant to which he was appointed interim Chief Financial Officer of the Company. There are also no family relationships between Mr. Galbraith and any director or executive officer of the Company, and he has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
ZYMEWORKS INC. | ||||||
(Registrant) | ||||||
Date: April 1, 2024 | By: | /s/ Kenneth Galbraith | ||||
Name: Title: |
Kenneth Galbraith Chair, President, Chief Executive Officer and interim Chief Financial Officer |
3
Document and Entity Information |
Mar. 31, 2024 |
---|---|
Cover [Abstract] | |
Amendment Flag | false |
Entity Central Index Key | 0001937653 |
Document Type | 8-K |
Document Period End Date | Mar. 31, 2024 |
Entity Registrant Name | Zymeworks Inc. |
Entity Incorporation State Country Code | DE |
Entity File Number | 001-41535 |
Entity Tax Identification Number | 88-3099146 |
Entity Address, Address Line One | 108 Patriot Drive |
Entity Address, Address Line Two | Suite A |
Entity Address, City or Town | Middletown |
Entity Address, State or Province | DE |
Entity Address, Postal Zip Code | 19709 |
City Area Code | (302) |
Local Phone Number | 274-8744 |
Written Communications | false |
Soliciting Material | false |
Pre Commencement Tender Offer | false |
Pre Commencement Issuer Tender Offer | false |
Security 12b Title | Common Stock, par value $0.00001 per share |
Trading Symbol | ZYME |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
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end
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